Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

被引：0
|
作者：
S Zhou
L Liu
H Li
G Eilers
Y Kuang
S Shi
Z Yan
X Li
J M Corson
F Meng
H Zhou
Q Sheng
J A Fletcher
W-B Ou
机构：
[1] Zhejiang Provincial Key Laboratory of Applied Enzymology,Department of Biotechnology and Biomedicine
[2] Yangtze Delta Region Institute of Tsinghua University,Department of Bioengineering
[3] College of Biology and Chemical Engineering,Department of Pathology
[4] Jiaxing University,Department of Biochemistry and Molecular Biology
[5] Brigham and Women’s Hospital and Harvard Medical School,undefined
[6] College of Life Sciences,undefined
[7] Zhejiang Sci-Tech University,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
mesothelioma; tyrosine kinases; PI3K/AKT/mTOR; PI3K/AKT/MDM2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2479 / 2488
页数：9
相关论文
共 50 条
  • [21] Targeting PI3K/mTOR Signaling in Cancer
    Emerling, Brooke M.
    Akcakanat, Argun
    CANCER RESEARCH, 2011, 71 (24) : 7351 - 7359
  • [22] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [23] Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
    Cheng, Haiying
    Shcherba, Marina
    Pendurti, Gopichand
    Liang, Yuanxin
    Piperdi, Bilal
    Perez-Soler, Roman
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 67 - 75
  • [24] Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
    A Bhatt
    P Bhende
    B Damania
    Infectious Agents and Cancer, 4 (Suppl 2)
  • [25] Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
    Westhoff, Mike-Andrew
    Faham, Najmeh
    Marx, Daniela
    Nonnenmacher, Lisa
    Jennewein, Claudia
    Enzenmueller, Stefanie
    Gonzalez, Patrick
    Fulda, Simone
    Debatin, Klaus-Michael
    PLOS ONE, 2013, 8 (12):
  • [26] Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
    LoPiccolo, Jaclyn
    Blumenthal, Gideon M.
    Bernstein, Wendy B.
    Dennis, Phillip A.
    DRUG RESISTANCE UPDATES, 2008, 11 (1-2) : 32 - 50
  • [27] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [28] Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
    Maira, Sauveur-Michel
    Furet, Pascal
    Stauffer, Frederic
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (01) : 137 - 155
  • [29] The PI3K/mTOR Pathway in Gallbladder Carcinoma
    Primiani, A.
    Shahid, M.
    Yilmaz, O.
    Ferrone, C. R.
    Borger, D. R.
    Iafrate, A. J.
    Zhu, A. X.
    Deshpande, V.
    LABORATORY INVESTIGATION, 2013, 93 : 173A - 173A
  • [30] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
12345